You are here: Industry Insights > Pfizer

News List

FDA approves Pfizer’s drugs for transthyretin amyloid cardiomyopathy pharmaceutical-technology
May 08, 2019
The US Food and Drug Administration (FDA) has approved Pfizer’s Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) to treat cardiomyopathy caused by transthyretin-mediated amyloidosis (ATTR-CM).
FDA speeds Bayer's J&J-Pfizer showdown with darolutamide 'priority' fiercepharma
May 06, 2019
Johnson & Johnson and the Pfizer-Astellas team have grown accustomed to a two-horse race in prostate cancer. But it may not be long before a third joins them.
Pfizer’ Talzenna leads latest CHMP highlights pharmatimes
April 29, 2019
Thirteen medicines were recommended for approval at the Committee’s April 2019 meeting, including two orphan medicines……
Pfizer, Lilly’s painkiller tanezumab shows mixed results in phase 3 osteoarthritis trial pharmaceutical-business-review
April 23, 2019
Pfizer and Eli Lilly’s phase 3 study has showed mixed results of painkiller tanezumab in the treatment of patients with osteoarthritis (OA).
Aduro Biotech Appoints CMO contractpharma
April 23, 2019
Nuyten brings expertise as a radiation oncologist specializing in cancer biology...
EC approves Pfizer’s NSCLC drug Vizimpro pharmaceutical-technology
April 23, 2019
EC approves Pfizer’s NSCLC drug Vizimpro
Pfizer and Lilly announce top-line results from long-term Phase 3 study of tanezumab in patients with osteoarthritis worldpharmanews
April 23, 2019
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg.
Pfizer, Eli Lilly's tanezumab yields mixed results in Phase III osteoarthritis trial firstwordpharma
April 21, 2019
Pfizer and Eli Lilly announced top-line results showing that the high dose of the NGF inhibitor tanezumab met two of three co-primary efficacy endpoints in a Phase III study……
Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older drugs
April 18, 2019
Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
Pfizer to use Concerto HealthAI technology for cancer treatments pharmaceutical-technology
April 12, 2019
Pfizer has partnered with patient-centred research firm Concerto HealthAI to fast-track actionable patient insights for investigational and commercialised cancer therapies...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 83 84 Next page